Jens Uwe Blohmer
Overview
Explore the profile of Jens Uwe Blohmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
344
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Uwe Blohmer J, et al.
Clin Transl Med
. 2024 Apr;
14(4):e1617.
PMID: 38664548
No abstract available.
2.
Siegler K, Plaikner A, Hertel H, Hasenbein K, Petzel A, Schubert M, et al.
J Minim Invasive Gynecol
. 2023 Nov;
31(2):110-114.
PMID: 37951567
Study Objective: This study aimed to present our case series of patients with early-stage cervical cancer undergoing simple trachelectomy (ST). Currently, radical trachelectomy is considered the most appropriate fertility-preserving procedure...
3.
Shams S, Lippold K, Uwe Blohmer J, Rohle R, Kuhn F, Karsten M
Ann Surg Oncol
. 2020 Dec;
28(6):3232-3240.
PMID: 33263157
Background: Sentinel lymph node biopsy after technetium-99 (Tc) localization is a mainstay of oncologic breast surgery. The timing of Tc injection can complicate operating room schedules, which can cause increasing...
4.
Heitz F, Kummel S, Lederer B, Solbach C, Engels K, Ataseven B, et al.
Geburtshilfe Frauenheilkd
. 2019 Oct;
79(10):1110-1117.
PMID: 31656321
Oestrogen receptor beta (ER-β) is abundantly expressed in breast cancer (BC), but its impact on neoadjuvant chemotherapy outcome is unknown. Patients treated in the neoadjuvant GeparTrio trial with available tissue...
5.
Kuemmel S, Holtschmidt J, Gerber B, von der Assen A, Heil J, Thill M, et al.
J Clin Oncol
. 2019 May;
37(17):1490-1498.
PMID: 31042410
Purpose: The aim of the current work was to clarify whether a preoperative lymphoscintigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB). Patients And Methods: In a prospective,...
6.
Richter H, Hennigs A, Schaefgen B, Hahn M, Uwe Blohmer J, Kummel S, et al.
Geburtshilfe Frauenheilkd
. 2018 Jan;
78(1):48-53.
PMID: 29375145
The likelihood of pathological complete remission (pCR) of breast cancer following neoadjuvant chemotherapy (NACT) is increasing; most of all in the triple negative and HER2 positive tumour subgroups. The question...
7.
Kummel S, Paepke S, Huober J, Schem C, Untch M, Uwe Blohmer J, et al.
Eur J Cancer
. 2017 Aug;
84:1-8.
PMID: 28768217
Background: The GENEVIEVE study compared the pathological complete response (pCR) rate (ypT0/is ypN0/+) in patients with operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) treated with either...
8.
Furlanetto J, Jackisch C, Untch M, Schneeweiss A, Schmatloch S, Aktas B, et al.
Breast Cancer Res Treat
. 2017 Mar;
163(3):495-506.
PMID: 28315068
Purpose: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative...
9.
Hanusch C, Schneeweiss A, Loibl S, Untch M, Paepke S, Kummel S, et al.
Clin Cancer Res
. 2015 Apr;
21(13):2924-31.
PMID: 25825476
Purpose: Dual anti-HER2 blockade with trastuzumab/pertuzumab or trastuzumab/lapatinib in combination with anthracycline/taxane-based chemotherapy can reach pathologic complete response (pCR) rates of up to 60% in HER2-positive breast cancer. The DAFNE...
10.
Fontanella C, Lederer B, Gade S, Vanoppen M, Uwe Blohmer J, Costa S, et al.
Breast Cancer Res Treat
. 2015 Feb;
150(1):127-39.
PMID: 25677740
Obesity is associated with an increased risk of breast cancer (BC) and poorer outcome. We assessed the impact of body mass index (BMI) on pathological complete response (pCR), disease-free (DFS),...